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Clostridium difficile is a Gram-positive, anaerobic, endospore-forming gastrointestinal pathogen responsible for C. difficile-associated disease (CDAD) 2 in humans and animals with symptoms ranging in severity from mild cases of antibioticassociated diarrhea to fatal pseudomembranous colitis (1) (2) (3) (4) . Each year in North America, 1-3% of hospitalized patients receiving antibiotics become infected with C. difficile, leading to thousands of deaths and over $1 billion in associated costs to the health-care system (4 -6). C. difficile produces two primary virulence factors, toxin A (TcdA) and toxin B (TcdB), which are large (308 and 269 kDa, respectively) single-subunit exotoxins composed of a catalytic, a translocation, and a cell receptor binding domain (RBD) (7, 8) . It has been suggested TcdB is solely responsible for C. difficile virulence (9) , although a recent study found both TcdA and TcdB knock-out strains are capable of causing mortality in hamsters (10) . This latter finding is in agreement with earlier work that showed both anti-TcdA and anti-TcdB mAbs were required for full protection of hamsters from CDAD (11, 12) , and anti-TcdA mAbs were required for protection in mice (13) .
Patients suffering from CDAD are most commonly treated with metronidazole or vancomycin (2) . However, there are several emerging challenges warranting the development of novel therapeutics. First, there is no acute CDAD treatment targeting TcdA/B. These toxins are responsible for loss of epithelial barrier function in the colon by disrupting tight junctions and increasing membrane permeability, causing diarrhea and promoting severe inflammation (1, 7) . Second, hypervirulent strains of C. difficile, such as the NAP1/027 isolate, overexpress TcdA and TcdB (14) and have been associated with increased mortality rates and disease severity (15, 16) . Third, an estimated 20 -25% of patients suffering from CDAD experience symptomatic relapse after the initial infection is cleared, with 45% of these patients prone to subsequent relapses (17) . Taken together, there is a need for nonantibiotic-based reagents that target and inhibit TcdA and TcdB for CDAD therapy.
Individuals who are asymptomatic C. difficile carriers and patients who experience mild cases of CDAD tend to possess high anti-TcdA titers (18 -21) . Conversely, patients susceptible to relapsing C. difficile infection have low anti-TcdA immunoglobulin titers, specifically IgM, IgG2, and IgG3 isotypes (18, 22) . TcdA-neutralizing secretory IgA antibodies are also thought to play a role in regulating CDAD severity (23, 24) . Therefore, the introduction of antitoxin antibodies to patients suffering from severe C. difficile infection may be a therapeutically useful approach.
A limited number of animal and human studies have illustrated the effectiveness of antitoxin Abs for treatment of CDAD (25) . Babcock et al. (11) intraperitoneally administered antiTcdA and anti-TcdB mAbs to hamsters and found a significant reduction in hamster mortality in prophylactic, primary disease and relapse models when both antitoxin mAbs were administered. A recently completed human trial involving these two mAbs appears promising for treating CDAD relapse (26) . In another study, intravenous administration of anti-TcdA mAbs raised against the RBD followed by oral challenge with C. difficile resulted in protection of mice (13) . Elsewhere, a toxoid vaccine given by the intraperitoneal route to hamsters conferred protection against oral C. difficile challenge (27) , and mice vaccinated with DNA encoding the TcdA RBD resulted in full protection from oral TcdA challenge (28) . In humans, a number of studies have reported intravenous immunoglobulin therapy to be successful for the treatment of severe CDAD (29 -34) , although most lacked proper control groups. Intravenous immunoglobulin involves administration of high concentrations (150 -400 mg/kg) of human immunoglobulins from healthy donors that are thought to contain neutralizing antitoxin antibodies, because an estimated 60% of healthy adults have detectable TcdA-and TcdB-specific serum IgG antibodies (21) .
Given that C. difficile toxins rely on attachment to epithelial cells for entry (7, 8) , the toxins could conceivably be neutralized within the lower gastrointestinal tract, thereby preventing the critical first step in CDAD pathogenesis. In animals, orally administered bovine immunoglobulin concentrate containing TcdA-and TcdB-neutralizing IgGs were able to prevent hamster mortality when used as a prophylactic (35) and protected rats from the enterotoxic effects of TcdA in vivo (36) . Chicken IgY antibodies specific for toxin RBDs were shown to reduce hamster mortality when administered orally to infected animals (12) . In humans, there have been limited reports on CDAD therapy with orally delivered Abs. Tjellström et al. (37) reported the successful treatment of a 3 1 ⁄ 2-year-old boy suffering from severe CDAD with IgA antibody orally. Warny et al. (38) and Kelly et al. (39) examined the passage of antitoxin bovine IgG through the human gastrointestinal tract and found a significant reduction in IgG activity, likely due to proteolytic degradation within the upper gastrointestinal tract. The limited success of both oral and systemic antitoxin immunotherapy in clinical settings has likely been hampered by the high immunoglobulin dose requirements (150 -400 mg/kg), the associated costs of these doses, and a lack of published clinical data showing the effectiveness of these treatments.
Alternatives to mAbs for antitoxin immunotherapy are variable heavy-chain single-domain antibodies (V H Hs), which are isolated from the heavy-chain IgG (HCAb) of Camelidae species (40, 41) . These domains maintain many characteristics of conventional mAbs, including high target affinity (42) and specificity, with the added advantages of small size (ϳ15 kDa), easy genetic manipulation, amenability to library screening and selection (43) , inherent thermal and proteolytic stability (44 -46) , and high yield, low cost recombinant production in expression hosts such as bacteria (47) , yeasts (48) , plants (49) , and mammalian cells (50) (reviewed in Refs. [51] [52] [53] ). An increasing number of V H Hs have been isolated against targets relevant to infection and immunity (reviewed in Ref. 54 ). Several of these V H Hs were effective neutralizers of toxins, viruses, and enzymes as follows: scorpion toxin AahIЈ (55, 56) ; Escherichia coli heat-labile toxin (57); foot and mouth disease virus (58); ART2.2, an ecto-enzyme related to ADP-ribosylating bacterial toxins (59); verotoxin 1 (60); HIV-1 envelope protein gp120 (61); rotovirus (62, 63) ; and p2 phage (64) . These V H Hs neutralized or inhibited the function of their targets by blocking enzyme-active sites (59), preventing protein-receptor binding through site-specific binding or steric hindrance (56, 57) , and by possibly inducing conformational changes in the target protein (62) .
Here, we set out to isolate V H Hs capable of binding and neutralizing C. difficile TcdA and TcdB. We hypothesized that V H Hs targeting the RBD region of toxin will block the toxinreceptor interaction, thereby preventing toxin entry into the host cell, which is a critical initial step in the TcdA/B mechanism of action (7). To do so, an immune llama V H H phage display library was constructed and panned with recombinant RBD fragments. The isolated V H Hs were then characterized for their ability to bind native toxins and recombinant RBD fragments and the nature and relative positioning of epitopes. In addition, the ability of V H Hs to neutralize toxins in an in vitro cell cytotoxicity assay was assessed. These findings and the potential applications of V H Hs in treating infectious disease are discussed.
EXPERIMENTAL PROCEDURES
Purification of Toxins and Recombinant Fragments-TcdA and TcdB were isolated from C. difficile strain 10463 (ATCC, Manassas, VA) as described previously (65) and were stored in 50 mM Tris-HCl buffer, pH 7.5, at 4°C. Recombinant fragments of TcdA (amino acid residues 2304 -2710) and TcdB (amino acid residues 2286 -2366), which are fragments of the RBD, were cloned (as a BamHI-HindIII fragment for tcdA and a BamHI-EcoRI fragment for tcdB) into pTrcHisB (Invitrogen), transforming E. coli DH5␣MCR. Expression was induced by isopropyl 1-thio-␤-D-galactopyranoside, and cells were harvested and lysed in a French pressure cell, and proteins TcdA-RBD-f1 and TcdB-RBD-f1 were purified by immobilized metalaffinity chromatography. Recombinant RBD fragments were dialyzed into PBS, pH 7.3, and stored at 4°C.
Llama Immunization and Serum Response-One male llama (Lama glama) was immunized by subcutaneous lower back injection of TcdA-RBD-f1 and TcdB-RBD-f1 antigens. On day 1, 200 g of each antigen diluted in PBS to 1 ml was injected with 1 ml of Freund's complete adjuvant (Sigma). Three more injections of 100 g of each antigen ϩ Freund's incomplete adjuvant (Sigma) were performed on days 22, 36, and 50. A final injection of 100 g of each antigen with no adjuvant was performed on day 77. Preimmune blood was drawn before the first injection on day 1 and served as a negative control. Blood (10 -15 ml) was collected on days 29, 43, 57, and 84. Preimmune and postimmune total serum was analyzed for a specific response to TcdA-RBD-f1 and TcdB-RBD-f1 by ELISA on day 57 (see below). Llama serum from day 84 was fractionated as before (66) . The resulting fractions, A1 (HCAb), A2 (HCAb), G1 (HCAb), and G2 (conventional IgG), were analyzed for specific binding to TcdA-RBD-f1 and TcdB-RBD-f1 by ELISA. Briefly, 5 g of TcdA-RBD-f1 or TcdB-RBD-f1 diluted in PBS was coated overnight (100 l/well, 18 h, 4°C) in 96-well Maxisorp TM plates (Nalge Nunc International, Rochester, NY). Plates were blocked with bovine BSA and washed with PBS-T (PBS ϩ 0.05% (v/v) Tween 20), and serial dilutions of preimmune total serum, postimmune total serum (day 57), and fractionated serum (day 84; 100 g/ml starting concentration) were applied. After incubation at room temperature for 1.5 h and washing with PBS-T, goat anti-llama IgG (1:1,000 in PBS) was added for 1 h at 37°C. After washing with PBS-T, pig anti-goat IgG-HRP conjugate (1:3,000 in PBS) was added for 1 h at 37°C. A final PBS-T wash precluded the addition of 100 l/well TMB substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD) for 10 min. The reaction was stopped with 100 l/well 1 M H 3 PO 4 and read on a Bio-Rad plate reader at 450 nm.
Library Construction and Selection of Toxin-binding V H Hs-Library construction and panning were performed essentially as described previously (67) (68) (69) . Total RNA was isolated from ϳ5 ϫ 10 6 lymphocytes collected on day 84 post-immunization using the QIAamp RNA blood mini kit (Qiagen, Mississauga, Ontario, Canada). About 5 g of total RNA was used as template for first strand cDNA synthesis with oligo(dT) primers using the first-Strand cDNA synthesis kit (GE Healthcare). The cDNA was PCR-amplified by an equimolar mix of three variable region-specific sense primers (MJ1, 5Ј-GCCCA-GCCGGCCATGGCCSMKGTGCAGCTGGTGGAKTCTGG-GGGA-3Ј; MJ2, 5Ј-CAGCCGGCCATGGCCCAGGTAAAG-CTGGAGGAGTCTGGGGGA-3Ј; and MJ3, 5Ј-GCCCA-GCCGGCCATGGCCCAGGCTCAGGTACAGCTGGTGGA-GTCT-3Ј) and two antisense CH2-specific primers (CH2, 5Ј-CGCCATCAAGGTACCAGTTGA-3Ј and CH2b3, 5Ј-GGTA-CCTGTCATCCACGGACCAGCTGA-3Ј). Briefly, the PCR mixture was set up in a total volume of 50 l with the following components: 1-3 l of cDNA, 5 pmol of MJ1-3 primer mixture, 5 pmol of either CH2 or CH2b3 primers, 5 l of 10ϫ reaction buffer, 1 l of 10 mM dNTP, and 2.5 units of TaqDNA polymerase (Hoffmann-La Roche). The PCR protocol consisted of an initial step at 94°C for 3 min, followed by 30 cycles of 94°C for 1 min, 55°C for 30 s, 72°C for 30 s, and a final extension step at 72°C for 7 min. The amplified PCR products were run in a 1% agarose gel, and two major bands were observed as follows: a band of about 850 bp, corresponding to conventional IgG, and a second band of around 600 bp, corresponding to HCAbs. The smaller bands were cut and purified using the QIAquick gel extraction kit (Qiagen) and re-amplified in a second PCR in a total volume of 50 l using 1 l of DNA template, 5 pmol of each of MJ7 primer (5Ј-CATGTG-TAGACTCGCGGCCCAGCCGGCCATGGCC-3Ј) and MJ8 primer (5Ј-CATGTGTAGATTCCTGGCCGGCCTGGCCT-GAGGAGACGGTGACCTGG-3Ј), 5 l of 10ϫ reaction buffer, 1 l of 10 mM dNTP, and 2.5 units of TaqDNA polymerase. The PCR protocol consisted of an initial step at 94°C for 3 min, followed by 30 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for 1 min and a final extension step at 72°C for 7 min. The amplified PCR products, ranging between 340 and 420 bp and corresponding to V H H fragments of HCAbs, were purified using the QIAquick PCR purification kit (Qiagen), digested with SfiI restriction enzyme (New England Biolabs, Pickering, Ontario, Canada), and re-purified using the same kit.
Eighty micrograms of pMED1 phagemid (67) was digested with SfiI overnight at 50°C. To minimize self-ligation, 20 units of XhoI and PstI restriction enzymes were added, and the digestion reaction was incubated for an additional 2 h at 37°C. Sixty micrograms of digested phagemid DNA was ligated with 6 g of digested V H H fragments for 3 h at room temperature using LigaFast Rapid DNA ligation system (Promega, Madison, WI) and its protocol. The ligated materials were purified using the QIAquick PCR purification kit in a final volume of 100 l and electroporated in 5-l portions into commercial electrocompetent TG1 E. coli cells (Stratagene, La Jolla, CA) as described previously (67) . The size of the library was determined as described previously (67) . Colony-PCR and sequencing involving 20 colonies showed all tested clones had unique V H Hs (67) . The library was grown for 2 h at 37°C, 250 rpm in the presence of 2% (w/v) glucose. The bacterial cells were pelleted, resuspended in 2ϫ YT/Amp/Glu (2ϫ YT medium with 100 g/ml ampicillin and 2% (w/v) glucose) with 35% (v/v) glycerol, and stored at Ϫ80°C in small aliquots.
Panning experiments were essentially performed as described previously (41) . Five milliliters of the library was thawed on ice and grown in 2ϫ YT/Amp/Glu for about 2 h at 37°C (A 600 ϭ 0.4 -0.5). Cells were subsequently infected with 20ϫ excess M13KO7 helper phage (New England Biolabs) for 1 h at 37°C. The culture was then centrifuged at 4°C, and infected cell pellets were resuspended in 200 ml of 2ϫ YT/Amp with 50 g/ml kanamycin and incubated overnight at 37°C and 250 rpm. The phage particles in culture supernatant were incubated with 1/5 volume of 20% PEG 6000, 2.5 M NaCl on ice for 1 h and centrifuged at 10,000 rpm for 15 min. The phage pellets were resuspended in 1.5 ml of sterile PBS, titrated, and used as input phage for panning. For panning, 96-well Maxisorp TM plates were coated with 20 g of TcdA-RBD-f1 or TcdB-RBD-f1 overnight at 4°C. The wells were rinsed with PBS and blocked with PBS, 1% (w/v) casein for 2 h at 37°C. Approximately 10 12 phage was added to the blocked wells and incubated for 2 h at 37°C. After 10ϫ washing with PBS, 0.1% (v/v) Tween 20, the bound phage was eluted with 0.1 M triethylamine, neutralized with 1 M Tris-HCl, pH 7.4, and mixed with exponentially growing TG1 cells. Titration of eluted phage was performed, and infected bacterial cells were superinfected with M13K07 and grown overnight at 37°C. The purified phage from the overnight cul-ture was used as the input for the next round of panning. The panning was continued for three more rounds following the same procedure except that the amount of coated RBD fragments was reduced to 15, 10, and 5 g for the second, third, and fourth rounds of panning, respectively.
Individual TG1 colonies obtained after round four of panning were subjected to phage ELISA screening, essentially as described elsewhere (66), with the exception that 5 g/ml toxin (TcdA and TcdB) and recombinant fragments (TcdA-RBD-f1 and TcdB-RBD-f1) were coated onto microtiter plates. All positive clones were sent for DNA sequencing. Unique clones that gave high phage ELISA signals were selected for subcloning, large scale expression, and purification. A total of seven antiTcdA and seven anti-TcdB clones were selected. Expression and Purification of V H Hs-Phagemid vectors containing the DNA of selected V H H clones were purified using the Qiagen miniprep kit. Of the 14 V H Hs, 11 clones were PCR-amplified from the pMED1 phagemid vector with either BbsI1-V H H (5Ј-TATGAAGACACCAGGCCCAGGTAAAG-CTGGAGGAGTCT-3Ј) or BbsI2-V H H (5Ј-TATGAAGA-CACCAGGCCCAGGTGCAGCTGGTGGAGTCT-3Ј) sense primers and BamHI-V H H (5Ј-TTGTTCGGATCCTGAGGA-GACGGTGACCTG-3Ј) antisense primer. These PCR fragments were digested with BbsI and BamHI restriction enzymes and ligated into the similarly digested pSJF2H expression vector (68) . Three of the 14 clones contained internal BbsI or BamHI sites and were cloned into the pMED2 expression vector via digestion with SfiI. The vector pMED2 is a modified version of pSJF2H that contains SfiI restriction enzyme sites in its multiple cloning site. Because V H H sequences in pMED1 are flanked with SfiI restriction sites, no PCR amplification was required for subcloning. Upon ligation, all plasmids were transformed into electrocompetent TG1 E. coli and selected on LB agar plates ϩ 100 g/ml ampicillin. Colonies were screened by colony PCR for inserts, and the DNA was sequenced.
V H Hs were expressed using the 5-day M9 minimal media method (67) . After induction of protein expression, cell cultures were harvested at 6,000 rpm for 30 min (4°C), and the supernatant was decanted, and the periplasmic contents were extracted from the cell pellet. Briefly, each pellet was resuspended in 30 ml of ice-cold TES buffer (0.2 M Tris-HCl buffer, pH 8.0, 20% (w/v) sucrose, 0.5 mM EDTA) and incubated on ice for 30 min. Next, 40 ml of ice-cold 1/8 TES was added, incubated an additional 30 min on ice, and the slurry centrifuged at 12,000 rpm for 30 min (4°C). The resulting supernatant was dialyzed overnight into immobilized metal-affinity chromatography buffer A (10 mM HEPES buffer, pH 7.0, 500 mM NaCl) and purified as described previously (70) . Eluted fractions were analyzed by SDS-PAGE and Western blotting before being dialyzed into PBS. V H H concentrations were determined by absorbance measurements at 280 nm using theoretical molecular weight and extinction coefficients calculated with the ExPASy ProtParam Tool (71) .
ELISA-ELISA was used to determine whether the purified antitoxin V H Hs recognized native TcdA or TcdB and recombinant TcdA-RBD-f1 or TcdB-RBD-f1 fragments. Equimolar concentrations of proteins (BSA, TcdA, TcdB, TcdA-RBD-f1, and TcdB-RBD-f1) were coated overnight in 96-well microtiter plates at 4°C. The next day, wells were blocked with 3% (w/v) skim milk diluted in PBS-T. After washing with PBS-T, purified V H Hs at concentrations as high as 10 g/ml were added to wells with the various coated antigens for 1 h at 37°C. Wells were washed with PBS-T, and rabbit anti-His 6 IgG conjugated to HRP (Cedarlane, Burlington, Ontario, Canada) diluted 1:2,500 in PBS was added for 1 h at room temperature before another set of five washes. Rabbit anti-His 6 IgG-HRP did not recognize the N-terminal His 6 epitope tags on recombinant RBD fragments (data not shown). Binding was detected with TMB substrate (Kirkegaard & Perry Laboratories), and the reactions were stopped with 1 M H 3 PO 4 , and the absorbance was read at 450 nm. All conditions were performed in triplicate, and the reported values are representative of two independent experiments.
A second ELISA was performed with differentially temperature-treated TcdA to determine whether the V H Hs recognized linear or conformational epitopes. Briefly, TcdA (5 g/ml) was exposed to the following conditions for 30 min: 4, 20, 37, 50, 60, and 70°C. After temperature treatment, 100 l of TcdA was coated in 96-well microtiter plates overnight at 4°C, and the assay was performed essentially as described above, except that 0.05-1 g/ml of V H H was used. All conditions were performed in duplicate, and the reported values are representative of two independent experiments.
Western Blotting-Western blots containing TcdA were probed with anti-TcdA V H Hs or control anti-TcdA IgG (PCG4; Novus Biologicals, Littleton, CO) to determine whether the V H Hs recognized linear or conformational epitopes. For denaturing SDS-PAGE Western blots, TcdA (0.75 g/lane), A4.2 V H H (1 g/lane), and PCG4 IgG (1 g/lane) were separated on 12.5% SDS-polyacrylamide gels under reducing conditions and transferred to PVDF membranes at 100 V for 1 h. Membranes were blocked for 1 h with 5% (w/v) BSA diluted in PBS-T followed by probing with various V H Hs (25 g/10 ml blocking buffer) or PCG4 (10 g/10 ml blocking buffer) for 1 h. Membranes were washed four times in PBS-T followed by addition of the following: (i) mouse anti-His 6 IgG-alkaline phosphatase (AP) conjugate (Abcam, Cambridge, MA) diluted 1:5,000 in blocking buffer, or (ii) HisDetector TM nickel-AP conjugate (Mandel Scientific, Guelph, Ontario, Canada) diluted 1:5,000 in blocking buffer, or (iii) goat anti-mouse IgG-AP conjugate (CedarLane) diluted 1:10,000 in blocking buffer for 1 h. After a final set of four washes, membranes were subjected to AP substrate (Bio-Rad) for 7 min, washed in distilled H 2 O, and air dried.
For native PAGE Western blots, TcdA, V H H, and PCG4 (concentrations as above) were separated on 8% polyacrylamide gels (without SDS) at 100 V for 2 h on ice. Next, gels were transferred to PVDF membranes at 20 V for 14 h at 4°C. Membranes were blocked, probed, washed, and detected using the same protocol as for SDS-PAGE Western blots.
Size Exclusion Chromatography and Surface Plasmon Resonance Analyses-Size exclusion chromatography was performed on all purified V H Hs using a Superdex TM 75 column (GE Healthcare) as described earlier (72) under the control of an AKTA TM FPLC. Fractions from the size exclusion column were then used for affinity measurements. The binding kinetics for the interaction of antitoxin V H Hs and TcdA or TcdB were determined by surface plasmon resonance (SPR) using a Biacore 3000 biosensor system (GE Healthcare). A total of 10,377 resonance units (RUs) of TcdA and 5,980 RUs of mouse IgG 13D9 control (73) were immobilized on a CM5 sensor chip (GE Healthcare). Anti-TcdA V H H affinity measurements were carried out in HBS-EP running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) P20 surfactant) at a flow rate of 40 l/min. Surfaces were regenerated by washing with either running buffer or 10 mM glycine, pH 2.0. Initial attempts to immobilize TcdB directly onto a CM5 sensor chip were unsuccessful due to the low pI (theoretical pI ϭ 4.42) of the toxin. We biotinylated TcdB with the EZ-Link Sulfo-NHS-LC-LC-Biotin kit from Pierce and were successful at immobilizing 825 RUs onto a streptavidin-coated CM5 sensor chip. However, because of the size difference of TcdB-biotin (269 kDa) compared with streptavidin (53 kDa), not all streptavidin sites were occupied, and roughly one TcdB-biotin was immobilized for every seven streptavidin molecules. Furthermore, no binding was observed between the anti-TcdB V H Hs and immobilized TcdB-biotin. We were able to collect data on the V H HTcdB-RBD-f1 interaction by immobilizing TcdB-specific V H Hs onto the CM5 sensor chip (RUs ranging from 215 to 1209) and injecting TcdB-RBD-f1 at 20 l/min. The IgG 13D9 or human single-domain antibody HVHP420 (72) served as controls. In all cases, data were analyzed with BIAevaluation 4.1 software (GE Healthcare).
In addition to obtaining binding kinetic data, we also used Biacore co-injection experiments to determine whether our V H Hs could bind unique, nonoverlapping epitopes on TcdA. Briefly, 80 l of the first V H H diluted in HBS-EP buffer to a concentration of 20ϫ its K D value was injected over 10,287 RUs of immobilized TcdA at 40 l/min. Following injection of the first V H H, buffer or a second V H H (80 l total volume, at 20ϫ K D ) was injected at 40 l/min over the TcdA surface already saturated with the first V H H. Data were collected on all possible paired combinations of A4.2, A5.1, A20.1, and A26.8, in both orientations (i.e. each V H H acted as the first and second V H H). Data were collected and evaluated as described above.
Using Biacore, we also attempted to inhibit the V H H-TcdA interaction with two trisaccharides known to bind TcdA-RBD, to gain insight into the TcdA epitope recognized by our V H Hs. 6 -NH 2 -HOAc) 3 are two trisaccharides known to interact with the carbohydrate binding pockets of TcdA-RBD (this work and see Refs. 74 -76). Briefly, four V H Hs (i.e. A4.2, A5.1, A20.1, and A26.8) at K D concentrations were injected alone or in the presence of trisaccharide (2 mM) over immobilized TcdA (ϳ8000 RUs). The response obtained from the interaction of trisaccharide with TcdA was subtracted from the response generated by V H H ϩ trisaccharide co-injection experiments. The response of each V H H to TcdA in the presence of trisaccharide was then compared with the response generated by the V H H-TcdA interaction.
In Vitro Toxin Neutralization Assay-Human lung fibroblast (HLF) cells are sensitive to both TcdA and TcdB, and the HLF cell rounding assay is routinely used for analyzing the presence of C. difficile toxins in biological samples (11) . The assay was used here to determine whether antitoxin V H Hs could neutralize the cytopathic effects of TcdA and TcdB. HLF cells (IMR-90, ATCC CCL-186) were purchased from ATCC (Manassas, VA) and maintained in Eagle's minimal medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) at 37°C with 5% CO 2 . Cells were seeded in sterile 96-well microtiter plates (2 ϫ 10 4 cells 200 l Ϫ1 well Ϫ1 ) for 20 h, allowing for the formation of confluent monolayers. Initially, a dose-response experiment was conducted to find the minimum concentration of TcdA and TcdB, which induced 100% HLF cell rounding after 24-h post toxin addition. To do so, sterile-filtered TcdA or TcdB was added to wells containing confluent monolayers, giving final toxin A concentrations ranging from 500 ng/ml (1.6 nM) to 0.5 ng/ml (1.6 pM) and final toxin B concentrations ranging from 500 ng/ml (1.9 nM) to 0.5 ng/ml (1.9 pM). Each concentration was performed in triplicate, and the assay was performed twice. HLF cells were scored visually for rounding at various time points over 24 h. For all subsequent assays, 100 ng/ml (325 pM) of TcdA and 10 ng/ml (37 pM) of TcdB were used.
For experiments involving V H Hs, 20 l of purified and sterile-filtered V H Hs were added to HLF cells with 10 l of TcdA/B or 10 l of PBS. For experiments involving two and three V H Hs, the concentration of each V H H was reduced by 1 ⁄2 and 1 ⁄3, respectively, giving the same final concentrations as experiments involving only a single V H H. Importantly, V H Hs and toxin were not preincubated; rather, each was added directly to HLF monolayers at time ϭ 0 h. HLF cells containing PBS, V H H, toxin, or V H H ϩ toxin were scored visually for cell rounding using a confocal microscope at 24 h post antibody/toxin addition. Assays were performed in triplicate and repeated twice. Each assay was performed on fresh preparations of HLF cells, and V H Hs were from separate purifications. The purified TcdA and TcdB stock remained the same for all assays. Cell rounding was assessed using the cytopathic effect scoring system previously described (11).
RESULTS
Toxin Binding V H Hs Were Isolated-CDAD is caused by two high molecular weight toxins composed of enzymatic, translocation, and cell receptor binding domains (Fig. 1, A  and B) . To isolate V H Hs, which target the RBD of TcdA and TcdB, a llama was immunized with two recombinant RBD fragments, TcdA-RBD-f1 and TcdB-RBD-f1 (Fig. 1A ). An ELISA conducted on total serum from day 57 clearly showed a specific immune response for TcdA-RBD-f1 and TcdB-RBD-f1 compared with preimmune sera collected before immunization on day 0 (Fig. 1C) . A second ELISA performed on fractionated sera from day 84 indicated that HCAb and conventional IgG serum fractions recognized TcdA-RBD-f1 and TcdB-RBD-f1. For example, the G1 HCAb fraction was shown to specifically recognize both recombinant fragments and did not bind to two unrelated proteins PEB3 or CPS (Fig. 1D ). An immune llama V H H library was constructed in the pMED1 phagemid vector, and its size was estimated at 5 ϫ 10 7 individual transformants. Colonies arising from four rounds of panning against TcdA-RBD-f1 and TcdB-RBD-f1 were screened by phage ELISA, and the positive clones were subjected to DNA sequencing. Seven unique TcdA-specific and seven unique TcdB-specific binders, all determined to be V H Hs based on the presence of characteristic amino acids at positions 42, 49, 50, and 52 ( Fig. 2) , were subcloned into expression plasmids; their expression was targeted to the periplasm of TG1 E. coli and purified (Fig. 1E ) with yields ranging from 1.2 to 72.3 mg/l bacterial culture (Table 1) .
Functional Integrity of Toxin Binding V H Hs Was
Confirmed-Purified V H Hs were analyzed by Superdex TM 75 size exclusion chromatography, and as expected all were nonaggregating monomers (data not shown). ELISA demonstrated that 6 of 7 anti-TcdA V H Hs recognized native TcdA and TcdA-RBD-f1 and that none of the V H Hs cross-reacted with TcdB or TcdB-RBD-f1 (Fig. 3, A and C) . Of the seven anti-TcdB V H Hs tested, five recognized TcdB and TcdB-RBD-f1 and one clone (B5.2) also recognized TcdA (Fig. 3, B and D) . SPR analysis revealed six of seven anti-TcdA V H Hs specifically bound TcdA with equilibrium dissociation constants ranging from 290 nM for A19.2 to 2 nM for A20.1 ( Fig. 4; Table 1 ). The arrow shows full-length TcdA (308 kDa) and TcdB (269 kDa). C, ELISA demonstrating a total llama serum response for the recombinant RBD fragments. Serum was prepared from llama blood drawn 57 days after the initial immunization. Immune A, immune serum against TcdA-RBD-f1; immune B, immune serum against TcdB-RBD-f1; pre-immune, preimmune serum against TcdA-RBD-f1. D, ELISA demonstrating the llama heavy-chain IgG (HCAb) G1 fraction response was specific for the recombinant RBD fragments. Serum was fractionated from llama blood drawn 84 days after the initial immunization, and the G1 fraction shown did not recognize PEB3 or CPS, two unrelated antigens. E, SDS-PAGE profile of purified V H Hs (2 g per lane) isolated from the immune llama phage display library and characterized in this study. Although purified to homogeneity, some V H Hs produce a doublet on nonreducing SDS-polyacrylamide gels. Molecular mass markers (M) are given in kDa. NR, nonreducing.
Four of the clones had K D values ranging from 2 to 24 nM ( Table 1 ). All of the data collected fit a 1:1 binding model.
Analyzing the TcdB-binding V H Hs by SPR was more challenging. Initial attempts to immobilize TcdB onto the CM5 dextran biosensor chip were hindered, we believe, by the low theoretical pI of TcdB. An attempt to biotinylate TcdB for immobilization on a streptavidin-coated biosensor chip was equally as unsuccessful. To circumvent this problem, antiTcdB V H Hs were immobilized directly onto the CM5 dextran chips, and data were collected using various concentrations of TcdB-RBD-f1. Analyzable data could only be collected for three of seven anti-TcdB V H Hs, with affinity constants ranging from 100 to 400 nM ( Fig. 4; Table 1 ). Specific binding was detected for the other four anti-TcdB V H Hs; however, the data were nonanalyzable (supplemental Fig. S1 ).
TcdA-specific V H Hs Bind Linear and Conformational Epitopes-To gain insight into whether the TcdA-specific V H Hs recognized a linear or conformational epitope on TcdA, Western blotting with both denaturing SDS-PAGE and native PAGE was performed. First, only A19.2 recognized TcdA run under denaturing/reducing conditions (Fig. 3F) . The antiTcdA mAb PCG4 (77) , which was previously shown to recognize TcdA in Western blots (78) , confirmed that TcdA was transferred to the blot. The weak signal obtained from A19.2 relative to PCG4 is likely due to the low affinity (K D ϭ 290 nM) and/or lack of avidity of A19.2 for TcdA. In the absence of primary antibody, the secondary conjugates nickel-AP and goat anti-mouse IgG-AP did not bind TcdA as expected. The V H H A4.2 and PCG4 were included to confirm the functionality of the secondary conjugates. Under nondenaturing conditions (native PAGE), we originally probed V H H binding to TcdA with mouse anti-His 6 IgG-AP and found this secondary antibody to cross-react with TcdA in the absence of V H H (data not shown). To overcome this, the secondary antibody was replaced with nickel-AP. Using this secondary conjugate, the V H Hs A4.2, A5.1, A20.1, and A26.8 recognized native TcdA, although the nonbinding A1.3 essentially did not react with TcdA (Fig. 3G) . The nickel-AP secondary conjugate did not bind native TcdA in control blots. The diffuse signal and poor migration pattern of A4.2 V H H control is likely due to its high pI (theoretical pI,: 8.59). To confirm the presence of TcdA on native PAGE blots, PCG4 was used as a control. Just like anti-His 6 IgG-AP, the secondary antibody goat anti-mouse IgG-AP also bound TcdA in the absence of the primary probe, PCG4 in this case (Fig. 3G , see under "Discussion").
To further validate the binding of our V H Hs to conformational or linear TcdA epitopes, TcdA was exposed to various temperatures above and below its thermal unfolding mid- 
TABLE 1 Properties of anti-C. difficile toxin A and B V H H single-domain antibodies
The following abbreviations are used: NB, no binding detected by Biacore; N/A, binding detected by Biacore (see supplemental Fig. 1 (Fig. 3E) . Collectively, these results suggest the anti-TcdA V H Hs recognize a conformational epitope on TcdA, with the exception of A19.2, which recognizes denatured TcdA in ELISA (Fig. 3E ) and Western blot (Fig. 3F) . These TcdA epitopes must be located in the RBD region of TcdA because llama immunization and library panning were both performed with TcdA-RBD-f1, and because the V H Hs were shown to recognize this recombinant fragment by ELISA (Fig. 3A) . TcdA-specific V H Hs Neutralize TcdA in Vitro-HLF cytotoxicity assays were used to determine whether V H Hs could neutralize TcdA-or TcdB-induced HLF cell rounding. Dose-response experiments with TcdA and TcdB (Fig. 5A ) determined the minimum toxin concentrations capable of 100% cell rounding after 24 h to be 50 ng/ml (162 pM) and 5 ng/ml (18.6 pM), respectively. For all subsequent experiments, we used two times this minimum concentration (i.e. 100 ng/ml (325 pM) of TcdA and 10 ng/ml (37 pM) of TcdB). V H Hs had no effect on HLF cells when incubated in the absence of toxin A (Fig. 5B) . When V H Hs (at 1000 nM concentration) and TcdA were added simultaneously to HLF cells, six of seven anti-TcdA V H Hs inhibited TcdA-induced cell rounding 24 h post TcdA addition (Fig. 5,  B-E) , although neutralization capacity of A19.2 was not significant (see supplemental Table S1 for statistical analysis). The neutralizing capacity of the four strongest V H Hs (A4.2, A5.1, A20.1, and A26. We next asked if adding various combinations of V H Hs would enhance toxin neutralizing efficacy. All possible doublet and triplet combinations were tested, with concentrations adjusted such that final V H H concentrations were the same as neutralizing experiments involving single V H Hs. In general, doublet and triplet combinations improved toxin A inhibition significantly (Fig. 5, C-E ; supplemental Table S1 ) (although it appears that at 1000 nM, the beneficial effect of combination is masked to some degree due to the high V H H concentration usage). For example, at 10 nM, all doublet and triplet V H H combinations significantly inhibited cell rounding, although only one of six singlets (A26.8) remained significant. At 10 and 0.1 nM concentrations, doublets involving A4.2 were weaker neutralizers compared with other pairs, likely a reflection of the poorer affinity of A4.2 (K D ϭ 24 nM) relative to the other V H Hs. Although all triplets remained significant inhibitors of cell rounding at 0.1 nM, only one combination (A4.2/A5.1/A26.8) showed improved efficacy relative to each of its three possible doublet components. However, two sets of doublets (A5.1/A20.1 and A20.1/ A26.8) have neutralization potencies that are comparable with those of triplets. This is likely due to a combination of high affinity binding and recognition of nonoverlapping toxin A epitopes (see below and under "Discussion"). At 0.1 nM, which is at least 20ϫ lower than the K D values of V H Hs, A5.1/A20.1 and A20.1/A26.8 doublets and all four triplet combinations (Fig. 5E ) inhibited at least 50% of cell rounding 24 h after TcdA addition. In particular, the A20.1/A26.8 pair and A4.2/A20.1/A26.8 triplet were capable of inhibiting nearly 75% of cell rounding.
Collectively, the above data demonstrate that V H Hs binding the RBD region of TcdA provide an effective strategy for generating potent TcdA neutralizers. Furthermore, In experiments involving TcdA-specific V H Hs, TcdA was immobilized on CM5-dextran chips, and monomeric V H Hs were passed over at concentration ranges noted on each sensorgram, giving affinity constants ranging from 2 to 290 nM. In experiments involving TcdB-specific V H Hs, antibodies were immobilized on CM5-dextran chips, and TcdB-RBD-f1 ranging in concentration from 2 M to 200 nM was passed over, giving affinity constants ranging from 100 to 400 nM. Black lines represent raw data measurements, and gray lines represent fitted curves. Rate and affinity constants are given in Table 1. combinations of these V H Hs increase toxin neutralizing efficacy.
We also tested the neutralizing capacity of the anti-TcdB V H Hs. None of the three TcdB-specific V H Hs examined were capable of TcdB neutralization, even at a concentration of 1 M (data not shown).
TcdA-specific V H Hs Recognize Overlapping and Nonoverlapping Epitopes on TcdA-The observation that combining antiTcdA V H Hs increased TcdA neutralizing efficacy relative to single V H Hs at the same concentration (Fig. 5, C-E) suggested these antibodies recognized distinct, nonoverlapping epitopes. We performed co-injection Biacore experiments with pairs of V H Hs, in both orientations, to determine whether antibodies could bind TcdA simultaneously (Fig. 6) . Of the paired combinations, only those involving A20.1 V H H showed a significant increase in response consistent with theoretical R max values (ϳ160 -180 RUs) upon co-injection. This suggests that A20.1 is free to bind TcdA when A4.2, A5.1, or A26.8 are bound at saturating concentrations and also indicates the A20.1 epitope is distinct and does not hinder binding of the other three V H Hs. For A4.2, A5.1, and A26.8, only minor changes in response were seen upon co-injection with theoretical R max values not reached, an indication that the V H Hs were binding overlapping epitopes and hindering the binding of each other to TcdA (Fig.  6 ). This was confirmed by co-injection of all three of these V H Hs simultaneously (Fig. 7) . Taken together, our Biacorebased epitope mapping studies suggest A20.1 freely binds TcdA at a site that does not overlap with, or is sterically hindered by, A4.2, A5.1, or A26.8 binding. These V H Hs bind at sites on TcdA that hinder freely accessible binding of the others, suggesting these antibodies share a single epitope or bind epitopes in such close proximity to one another that it prevents unhindered interaction with sensor chip-immobilized TcdA. ture of TcdA-RBD was shown to contain seven carbohydrate binding pockets thought to be involved in cell receptor binding (74) . We asked whether TcdA neutralization was due to V H H binding in the TcdA-RBD carbohydrate binding pockets. Using Biacore and two trisaccharides capable of binding TcdA-RBD within these pockets, we were unable to inhibit the binding of our neutralizing V H Hs to TcdA in co-injection experiments ( Fig. 8 and supplemental Fig. S2 ). When both CD-grease and Le X -AmHex trisaccharides were used at concentrations above the K D values estimated from electrospray mass spectrometry (76) , 4 the trisaccharides bound to immobilized TcdA as detected by SPR, but carbohydrate binding did not prevent the binding of V H H fragments to TcdA (Fig. 8 and supplemental  Fig. S2 ). In additional Biacore experiments, we found that 10 mM concentrations of CD-grease trisaccharide (five times K D concentration) were free to bind TcdA saturated with V H H (Fig. 9) . Furthermore, V H H binding to TcdA was not inhibited in ELISA with trisaccharide concentrations as high as 10 mM (data not shown). Taken together, these data indicate our V H Hs do not inhibit free trisaccharides from accessing their binding sites on TcdA-RBD and that our V H Hs are not binding at sites occupied by the trisaccharides.
TcdA-specific V H Hs Neutralize Toxin A by Binding to Sites Other than the Carbohydrate Binding Pockets of Toxin-V

DISCUSSION
C. difficile is a gastrointestinal pathogen that causes CDAD with symptoms ranging from mild diarrhea to fatal pseudomembrane colitis. Patients infected with the Gram-positive bacterium are routinely treated with oral antibiotic therapy. However, hypervirulent C. difficile strains that express elevated levels of TcdA and TcdB are now common hospital isolates (2) and are making treatment more challenging. The increasing number of patients who relapse with C. difficile symptoms after antibiotic treatment is also of considerable concern. Because of the heavy antibiotic load, relapsing patients cannot repopulate their gastrointestinal tract with the normal complement of commensal microflora. Relapsing patients also mount poor 4 C. C. Ling, J. Klassen, and K. Ng, unpublished observations. In general, A4.2, A5.1, and A26.8 appeared to share an overlapping epitope as no significant increase in response was found upon injection of the second species. Conversely, A20.1 appeared to bind a distinct, nonoverlapping epitope. When A20.1 injections were followed by A4.2, A5.1, and A26.8 injections, there was an approximate doubling of total signal with the second injection. However, this was not observed with the reverse injection combinations, particularly A4.2 followed by A20.1 and A26.8 followed by A20.1, because the relatively fast off-rates of A4.2 and A26.8 compared with A20.1 resulted in very significant dissociation of these V H Hs from the surface before equilibrium binding of A20.1 was reached.
anti-TcdA immune responses, specifically low serum IgG and possibly secretory IgA titers. It has been shown that patients who do not relapse after antibiotic treatment, or are asymptomatic carriers of C. difficile, possess higher antitoxin A antibody titers. Collectively, this suggests the introduction of toxin-neutralizing antibodies may be an effective therapy to treat recurrent CDAD.
In this study, we set out to isolate a panel of llama single domain antibodies (V H Hs) that target TcdA or TcdB. We hypothesized that V H Hs that bind the C-terminal RBD of TcdA and TcdB will block toxin binding to host-cell receptors or prevent cellular uptake of the toxins. We based our experimental design on previous studies that illustrated successful neutralization of C. difficile toxins using antibodies targeting TcdA, or through RBD-based vaccines (11, 12, 28, 78, 82, 83) . We generated a V H H phage display library by immunizing a llama with recombinant RBD fragments and isolated V H H binders by panning this library with these same fragments. The isolated antibodies were well expressed in E. coli periplasm, yielding up to 72 mg/liter of culture all in a monomeric nonaggregating form, as expected, and recognized native TcdA/B isolated from C. difficile strain 10463 as well as recombinant RBD fragments. Given the high degree of TcdA-RBD sequence identity among different C. difficile strains, it is very likely that the current V H Hs also recognize TcdA from hypervirulent isolates. In characterizing the V H H-toxin interaction, we determined that most V H Hs recognized a conformational epitope on TcdA. Under denaturing Western blot conditions, only A19.2 V H H and control PCG4 IgG bound to TcdA. Conversely, in native PAGE blot analysis, all specific V H Hs tested bound to TcdA. However, when the V H H or PCG4 primary antibodies were omitted from the native blots, the secondary mouse anti-His 6 IgG-AP or goat anti-mouse IgG-AP antibodies bound to TcdA. This was not the case with the denaturing Western blots, indicating a genuine binding interaction between native (nondenatured) TcdA and secondary IgG antibody. Interestingly, the rabbit anti-His 6 IgG-HRP conjugate used in our ELISAs did not recognize TcdA when the primary antibody was omitted. Binding of TcdA to mouse mAbs has been reported (89) and found to occur through the Fab component (90) with TcdA possibly recognizing a carbohydrate on C H 1. Binding of our V H Hs was specific to TcdA, as shown by Biacore and ELISA, and could not possibly occur from glycosylation of the V H H because these domains do not contain putative glycosylation sites and were expressed in E. coli. The cross-reactivity of secondary mAbs encountered here reinforces the need to perform proper controls during immunoassays. When the cross-reacting secondary antibody was replaced with a nickel-AP conjugate, V H H We evaluated the ability of V H Hs to neutralize C. difficile toxins in a standard cytotoxicity assay. Six of the seven TcdAspecific V H Hs evaluated were neutralizing, with four being potent neutralizers, demonstrating that our llama immunization strategy involving the use of TcdA-RBD as an immunogen is an effective one for generating toxin-neutralizing antibodies. As shown by binding assays, neutralization was achieved by binding of V H Hs to sites other than the carbohydrate binding pocket of toxins. Clones A19.2 (K D ϭ 290 nM) and A24.1 (K D ϭ 260 nM) were the poorest neutralizers and also possessed the lowest affinities for TcdA. The potent neutralizers (A4.2, A5.1, A20.1, and A26.8) possessed much higher affinity for TcdA than A24.1 and A19.2, and all showed comparable efficacy. As such, efficacious toxin neutralization is dependent on high affinity binding to TcdA epitopes that are important in toxincell receptor contacts.
The structure of TcdA-RBD contains seven putative carbohydrate-binding sites (74, 91) , which are thought to interact with epithelial cell-surface receptors to mediate endocytosis (92) . The binding sites are spaced between 3 and 5 nm away from each other, and because of geometric constraints, all seven sites likely cannot access the cell-surface receptors simultaneously. Rather, four or five sites appear to be suitably presented for binding cell-surface carbohydrates simultaneously, depending on the rotational orientation of the RBD relative to the cell surface (74, 93) . The structure of the RBD thus strongly suggests that avidity is crucial to the strength of toxin binding to its cellular receptors.
To deduce the molecular mechanism of toxin neutralization, a competition experiment was performed to test whether V H Hs directly interfered with the binding of small carbohydrate ligands capable of interacting with individual binding sites. Because these small ligands do not compete directly with the binding of V H Hs, the neutralization activity of the V H Hs does not derive from a disruption of the portion of the receptor binding sites interacting with two synthetic trisaccharide ligands believed to bind to the central portion of the RBD carbohydrate-binding sites. These experiments do not rule out the possibility that V H H binding may occlude the binding of larger ligands occupying a more extended binding site. It is also possible that V H H binding may sterically interfere with the binding of multiple RBD-binding sites to ligands presented on a cell surface.
If an indirect, steric interference mechanism is operating, we hypothesized that the addition of more than one neutralizing V H H, each of which recognizes distinct epitopes on the TcdA-RBD, may provide an enhanced neutralizing potency through greater hindrance of toxin-cell receptor contacts. In fact, when various combinations of A4.2, A5.1, A20.1, and A26.8 were tested, their TcdA-neutralizing efficacy was greater than any of the V H Hs alone. These findings are similar to Nowakowski et al. (94) and Demarest et al. (95) who showed increased BoNT/Aand TcdA-neutralizing capacity, respectively, with a mixture of mAbs. Our observations suggested the V H Hs recognized distinct epitopes on TcdA, which was subsequently confirmed for one V H H (A20.1) by co-injection Biacore epitope mapping experiments (Fig. 6) . In contrast, the other potent neutralizers appeared to bind to overlapping epitopes on TcdA. These data explain the increased neutralizing capacity seen for pairs and triplet combinations containing A20.1, but they do not explain why some pairs (i.e. A5.1/A26.8) or triplet combinations (i.e. A4.2/A5.1/A26.8) show greater efficacy than these V H Hs on their own. The Biacore data indicated a 1:1 binding stoichiometry that is difficult to reconcile with the observation of enhanced neutralizing efficacy with mixed V H Hs binding to overlapping epitopes. The binding stoichiometry determination assumes a mainly active toxin surface, which may not be the case because our toxin preparations showed a significant amount of breakdown products (Figs. 1B and 3, F and G) . It is clear that the neutralization and Biacore experiments are not related methodologies and were employed to assess for two different effects. However, together they do not completely agree with the conclusion of "distinct epitopes." For example, one may have expected to see additive effects with the A4.2/ A20.1 doublet in neutralization assays and not with A4.2/A26.8 or A5.1/A26.8 doublets based on the epitope mapping results. The observed neutralization effect may be the net result of interplay of many factors, including K D , association and dissociation rate constants, k a and k d , the identity and overlapping nature of epitopes, stability of the V H Hs under the neutralization assay condition, and limitations of the assay. These factors may also explain why in several instances triplets were not better neutralizers than doublets. We are currently performing electrospray ionization mass spectrometry (ES-MS) assays (76) and solving co-crystal structures to determine the V H H:TcdA binding stoichiometry and TcdA epitopes, respectively. If the V H H to toxin binding stoichiometry is in fact greater than 1:1, the synergistic effect observed with V H Hs recognizing overlapping epitopes may be due to binding orientation effects.
Compared with other studies involving C. difficile toxin neutralization, our V H Hs performed well. First, TcdA and V H H were not preincubated together, which is routinely done before in vitro experiments involving neutralizing antibodies and toxins (11, 56, 63) . We felt the simultaneous addition of V H H and toxin to fibroblast cells was more representative of in vivo scenarios and did not bias our in vitro results by preincubating. Second, we used severalfold more TcdA (325 pM or 100 ng/ml) compared with the study of Babcock et al. (11) . However, different sources of TcdA, length of storage, storage conditions, and minor breakdown products may effect the concentrations of a given stock of TcdA, which cause cytotoxic responses in cell culture, making reliable comparisons between the two studies difficult. Babcock et al. (11) reported the most potent TcdA neutralizer (mAb 1B11) inhibited 50% TcdA-induced rounding at a concentration of 0.1 nM after 18 h. Although our individual V H Hs did not perform as well as mAb 1B11 after 24 h, A5.1/ A20.1 and A20.1/A26.8 pairs and most triplet V H H combinations prevented at least 50% cell rounding at a concentration of 0.1 nM, 24 h after toxin addition. Thus, our pooled V H Hs should serve as a very effective therapeutic mixture as they possess comparable efficacy to anti-TcdA mAbs currently in clinical trials. In addition, a range of structure-based and random mutagenesis approaches is available for further improving the binding affinities and neutralization efficacies of V H Hs.
We also found the isolated TcdB-specific V H Hs were not capable of neutralizing TcdB. Their apparent affinities for the TcdB-RDB-f1 fragment ranged from 100 to 400 nM, and it is not clear whether this affinity is insufficient for neutralization or if the epitopes these V H Hs were raised against are not involved with the binding of TcdB to cell-surface receptors. Although the anti-TcdB V H Hs recognized TcdB-RBD-f1 and native TcdB in ELISA (Fig. 3B) , we did not collect reliable SPR data for the V H H-TcdB interaction; rather, data were only collected against TcdB-RBD-f1, which may show significant structural differences when presented in the context of the whole toxin (93) . As such, the V H H affinities for TcdB may even be lower than the reported values above, and this could account for poor neutralization. There is also the possibility that the lack of neutralization of toxin B binding V H Hs is due to the fact that regions of TcdB other than the RBD are involved in host cell surface binding and cellular entry, as suggested previously (76, 96) . B5.2, in particular, cross-reacted with toxin A, and it would be interesting to determine its K D value as well as its neutralization potential toward toxin A. Although epitope mapping experiments were not carried out in the case of toxin B binders, the amino acid sequence data indicate that B5.2 probably uses the same D gene (KVVGGRL) as B13.6 (AVVGGVI) and B15.5 (KVVRGSL), suggesting that all three V H Hs may interact with the same epitope.
In conclusion, we isolated and characterized C. difficile toxin A-and B-specific V H Hs from an immune phage display library. We found several TcdA-specific V H Hs capable of neutralizing TcdA in vitro through high affinity interactions with TcdA-RBD. V H Hs are extremely stable antigen binding domains that are expressed at high yields in recombinant organisms and are capable of neutralizing infectious disease-related targets (54) . With respect to CDAD therapy, V H Hs could be administered systemically to target TcdA and TcdB, as they share high sequence homology with human V H domains and are thus well tolerated in humans (97) or formulated for oral administration to the gastrointestinal tract. Enhanced toxin-neutralizing efficacy should be obtainable by increasing their intrinsic affinity, blood circulation half-lives, size, and avidity through chimeric formats of anti-TcdA V H Hs linked to an Fc domain or through the generation of bi-or tri-specific antibody fusions with two or three anti-TcdA V H Hs recognizing unique epitopes. Although not neutralizing, the present toxin B-specific V H Hs could, nonetheless, enhance the neutralization efficacy of other toxin B-neutralizing V H Hs by a chelating effect when fused to them.
By targeting C. difficile virulence factors such as TcdA/B, selection pressure is removed from the organism, decreasing the chance of antibiotic resistance. A mutation in the RBD, which is well conserved among C. difficile isolates, including the hypervirulent 027 ribotype strains, is unlikely to benefit the organism, and in the event it does occur, the toxin may lose its ability to enter host cells. As such, anti-TcdA/B V H Hs are logical agents to explore for CDAD therapy. Our current efforts are focused on isolating TcdB-neutralizing V H Hs and stability engineering neutralizing V H Hs for greater acidic pH and protease resistance for oral therapeutic purposes.
